Tilman Brummer
Principal Investigator
Institute of Molecular Medicine and Cell Research
University of Freiburg
Stefan-Meier-Str. 17
79104 Freiburg
- +49 761 203-9610
- tilman.brummer@mol-med.uni-freiburg.de
- Homepage
Current position
Academic training
| 1992 - 1998 | Study of Biology (Diplom-Biologe), University of Freiburg |
Advanced academic qualifications
| 2003 | PhD equivalent (Dr. rer. nat.), graduated with Summa cum laude |
Postgraduate Positions
| Since 2017 | Heisenberg-Professorship W3, Institute of Molecular Medicine and Cell Research, University of Freiburg |
| 2013 - 2017 | Independent group leader within the Emmy-Noether- and Heisenberg programs of the Deutsche Forschungsgemeinschaft (DFG), Institute for Molecular Medicine and Cell Research, Faculty for Medicine, University of Freiburg |
| 2008 - 2012 | Independent Group leader within the Emmy-Noether-Program of the DFG, Faculty for Biology, University of Freiburg |
| 2003 - 2008 | Postdoctoral fellow, Signal Transduction Group (Prof. R. J. Daly), Cancer Research Program, Garvan Institute of Medical Research, Sydney, Australia |
| 1998 - 2003 | PhD student and postdoctoral fellow, Dept. Molecular Immunology, Max-Planck-Institute for Immunobiology, Freiburg |
Miscellaneous (Honors, Awards)
| 2015 | Heisenberg professorship of the DFG |
| 2014 | Heisenberg fellowship of the DFG |
| 2007 | Emmy-Noether fellowship of the DFG |
| 2003 | Hans-Spemann-Prize, Faculty of Biology, ALU |
| 2003 | Selected delegate for the 53th Meeting of the Nobel laureates |
Publications listed in PubMed®
Publications (based on CRC1479 funding)
Sigaud R, Albert TK, Hess C, Hielscher T, Winkler N, Kocher D, Walter C, Münter D, Selt F, Usta D, Ecker J, Brentrup A, Hasselblatt M, Thomas C, Varghese J, Capper D, Thomale UW, Hernáiz Driever P, Simon M, Horn S, Herz NA, Koch A, Sahm F, Hamelmann S, Faria-Andrade A, Jabado N, Schuhmann MU, Schouten-van Meeteren AYN, Hoving E, Brummer T, van Tilburg CM, Pfister SM, Witt O, Jones DTW, Kerl K, Milde T. MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas. Nat Commun. 2023 Jul 27;14(1):4533. doi: 10.1038/s41467-023-40235-8.
Brummer T, Zeiser R. The role of the MDM2/p53 axis in anti-tumor immune responses. Blood. 2023 Jul 19:blood.2023020731. doi: 10.1182/blood.2023020731. Epub ahead of print.
Heinrich K, Fischer LE, De Toni EN, Markwardt D, Roessler D, Beyer G, Günther M, Ormanns S, Klauschen F, Kunz WG, Fröhling S, Brummer T, Heinemann V, Westphalen CB. Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy. JCO Precis Oncol. 2023 Jun;7:e2200650. doi: 10.1200/PO.22.00650.
Rohrer L, Spohr C, Beha C, Griffin R, Braun S, Halbach S, Brummer T. Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase. Cell Commun Signal. 2023 Jun 14;21(1):136. doi: 10.1186/s12964-023-01146-9.
Langhammer M, Schöpf J, Jaquet T, Horn K, Angel M, Spohr C, Christen D, Uhl FM, Maié T, Jacobi H, Feyerabend TB, Huber J, Panning M, Sitaru C, Costa I, Zeiser R, Aumann K, Becker H, Braunschweig T, Koschmieder S, Shoumariyeh K, Huber M, Schemionek-Reinders M, Brummer T, Halbach S. Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model. Leukemia. 2023 May 9. doi: 10.1038/s41375-023-01916-x. Online ahead of print.
Langenbach M, Giesler S, Richtsfeld S, da Costa-Pereira S, Rindlisbacher L, Wertheimer T, Braun LM, Andrieux G, Duquesne S, Pfeifer D, Woessner NM, Menssen HD, Taromi S, Duyster J, Boerries M, Brummer T, Blazar BR, Minguet S, Turko P, Levesque MP, Becher B, Zeiser R. MDM2 inhibition enhances immune checkpoint inhibitor efficacy by increasing IL-15 and MHC class II production. Mol Cancer Res. 2023 Apr 18:MCR-22-0898. doi: 10.1158/1541-7786.MCR-22-0898. Epub ahead of print.
Avery TY, Köhler N, Zeiser R, Brummer T, Ruess DA. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. Front Oncol. 2022 Jul 27;12:931774. doi: 10.3389/fonc.2022.931774.
Corrales E, Levit-Zerdoun E, Metzger P, Kowar S, Ku M, Brummer T, Boerries M. Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts. Cell Commun Signal. 2021 Dec 20;19(1):123. doi: 10.1186/s12964-021-00801-3.
Spohr C, Poggio T, Andrieux G, Schönberger K, Cabezas-Wallscheid N, Boerries M, Halbach S, Illert AL, Brummer T. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo. Leukemia. 2022 Apr;36(4):970-982. doi: 10.1038/s41375-021-01490-0. Epub 2021 Dec 13.2021
Contact
